

eISBN: 978-1-68108-477-0
ISBN: 978-1-68108-478-7


eISSN: 2352-7633
ISSN: 2467-9593

Frontiers in Stem Cell and Regenerative Medicine Research

Volume 6

Editors:
Atta-ur-Rahman, *FRS*
Shazia Anjum

Bentham  Books



Frontiers in Stem Cell and Regenerative Medicine Research

(Volume 6)

Edited By

Atta-ur-Rahman, *FRS*

*Honorary Life Fellow, Kings College, University of Cambridge
Cambridge, UK*

&

Shazia Anjum

*Department of Chemistry, Cholistan Institute of Desert Studies
The Islamia University of Bahawalpur, Pakistan*

Frontiers in Stem Cell and Regenerative Medicine Research

Volume # 6

Editors: Prof. Atta-ur-Rahman and Dr. Shazia Anjum

ISSN (Online): 2352-7633

ISSN: (Print): 2467-9593

ISBN (Online): 978-1-68108-477-0

ISBN (Print): 978-1-68108-478-7

© 2017, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

Reprints and Revisions:

First published in 2017.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided “as is” without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.org



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 THE EMERGING ROLE OF MESENCHYMAL STEM CELL SECRETOME IN CARTILAGE REGENERATION	1
<i>Y gk'Ugqpi 'Vqj</i>	
INTRODUCTION	1
MESENCHYMAL STEM CELLS	3
MESENCHYMAL STEM CELL-BASED THERAPIES FOR CARTILAGE REPAIR	3
MSC SECRETOME	4
Cell Recruitment	5
Cell Survival	6
Cell Proliferation	6
Cell Differentiation and Matrix Synthesis	7
Immunomodulation	7
MSC EXTRACELLULAR VESICLES	8
CELL-FREE THERAPIES FOR CARTILAGE REPAIR	9
Growth Factors, Cytokines and Chemokines	9
Exosomes	10
CONCLUSION	11
CONFLICT OF INTEREST	11
ACKNOWLEDGEMENTS	11
REFERENCES	12
CHAPTER 2 THE POTENTIAL CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM THE DENTAL PULP (DPSCs) FOR BONE REGENERATION	21
<i>Cpc'Tkac'Ecugkt q. 'Tvk'Crnkxgu. 'Ufjck'Ucpxqu'Rgf tqc. 'Lqu' 'O ki wgn</i>	
<i>Eco rqu 'fp' u'Ngcn'Tgku. 'Lqu' 'F qo lpi qu'Ucpxqu. 'Ectrc' 'O gpf qp±c. 'Nw'u' 'O ki wgn</i>	
<i>Cw'f g'and' 'Cpc' 'Eqrwg' 'O cwt 'kq</i>	
INTRODUCTION	22
DENTAL STEM CELLS	23
Tooth Anatomy and the DPSCs Niche	23
Stem Cells from Human Permanent Teeth Dental Pulp	25
<i>Phenotypic Features</i>	26
<i>Differentiation Capacities</i>	27
Stem Cells from Human Deciduous Teeth Dental Pulp	28
Stem Cells from Other Dental-Related Tissues	28
<i>Stem Cells from Human Permanent Teeth Apical Dental Pulp (APDCs/SCAPs)</i>	28
<i>Stem Cells from Human Dental Follicle (DF-MSCs)</i>	29
<i>Stem Cells from Human Periodontal Ligament (PDLSCs)</i>	29
DPSCs from Other Species	30
Isolation and Culture Methods	32
Immunomodulatory Properties	35
Pro-Angiogenic Properties	36
Cryopreservation of Pulp Tissues and Cells	37
DPSCs Potential in Tissue Regeneration Applications	37
IN VITRO INDUCTION OF MINERALIZED TISSUE FORMATION	38
Association to Biomaterials for Mineralized Tissue Regeneration	43
<i>Bone Tissue Regeneration</i>	43
<i>DPSCs for Dental Tissue Regeneration</i>	49

Other Tissue Regeneration Applications	51
Other Neural Damage Models have also been Explored	53
FINAL REMARKS	53
CONFLICT OF INTEREST	54
ACKNOWLEDGEMENTS	54
ABBREVIATIONS	55
REFERENCES	56
CHAPTER 3 MESENCHYMAL STEM CELLS IN REGENERATIVE MEDICINE: THE CHALLENGES AND THE OPPORTUNITIES	71
<i>Ej gp'Mcp.'Nkwp'Ej gp.'I cpi {cpi 'J w.'J ckø gk'Nw'and'Nz,kp'Mcp</i>	
INTRODUCTION	71
PERSPECTIVE OF MSCS IN REGENERATIVE MEDICINE	74
THE PHENOTYPICAL CHARACTERISTICS OF MSCs AND THE RELATED CHALLENGES	74
Typical In Vitro Morphological Features of MSCs	74
Candidate Markers of MSC	74
<i>Main Challenges</i>	84
Other Essential Phenotypical Characteristics of MSCs	84
<i>Stemness: Self-renewal and Differentiation Capacity of MSCs</i>	84
<i>Immunoprivileged Status of MSCs</i>	85
<i>Immunomodulatory Effects of MSCs</i>	87
<i>Trophic Effects of MSCs</i>	88
<i>Anti-apoptotic Effects of MSCs</i>	89
<i>The Safety Profile</i>	89
<i>Easy Accessibility</i>	91
THE CLINICAL OPPORTUNITIES AND THE CHALLENGES	91
The Common Theoretical Challenges	92
The Common Practical Challenges	93
MSCs in Tissue Repair	93
<i>The Challenges</i>	94
MSCs in Bone and Cartilage Diseases	94
<i>The Challenges</i>	95
CONCLUSION AND FUTURE DIRECTIONS	95
CONFLICT OF INTEREST	96
ACKNOWLEDGEMENTS	96
REFERENCES	96
CHAPTER 4 LIVER REGENERATION: AN UPDATE ON THE ROLE OF NON-PARENCHYMAL CELLS	105
<i>'Dgcvt k' 'Ctvgr. 'Cpvqpk 'Ckct g/. 'Lqpc 'O cts wg/. 'Ckqt 'Dgp gf kexq'and'Gpt kswg'J kvt kq'</i>	
INTRODUCTION	105
Non Parenchymal Cells within the Liver Microenvironment	106
NON PARENCHYMAL CELLS IN LIVER REGENERATION	108
Liver Sinusoidal Endothelial Cells	108
Liver Macrophages	111
Hepatic Stellate Cells	113
NPCS ROLE IN THE DEVELOPMENT OF BIOARTIFICIAL LIVER SYSTEMS	115
CONCLUDING REMARKS	118
CONFLICT OF INTEREST	119
ACKNOWLEDGEMENTS	120
REFERENCES	120

CHAPTER 5	CARDIOGENESIS AND REPAIR: INSIGHTS FROM DEVELOPMENT AND CLINICAL TRIALS	128
	<i>Uj ggpc 'Tclw 'F cplgrl' OeEwntqej . 'Crkngt 'E0Y ctf 'and 'Ej cpf t c 'Xkay cpcvj cp</i>	
	INTRODUCTION	128
	MODEL ORGANISMS IN THE STUDY OF CARDIOGENESIS	130
	Introduction to Cardiac Development	130
	<i>Fruit Fly Cardiac Development</i>	130
	<i>Zebrafish Cardiac Development</i>	132
	<i>Toad Cardiac Development</i>	134
	<i>Chicken Cardiac Development</i>	135
	<i>Mouse Cardiac Development</i>	137
	<i>Core Developmental Pathways</i>	138
	INSIGHTS FROM STEM CELL BIOLOGY	139
	PRE-CLINICAL APPLICATIONS	140
	Hematopoietic Stem and Progenitor Cells	143
	Mesenchymal Stem Cells	143
	Skeletal Myoblasts	144
	Cardiac and Endothelial Stem and Progenitor Cells	144
	Embryonic and Induced Pluripotent Stem Cells	145
	Exosomes and Secretory Factors	145
	CLINICAL APPLICATIONS	145
	CONCLUSION	148
	CONFLICT OF INTEREST	150
	ACKNOWLEDGEMENTS	150
	REFERENCES	150
CHAPTER 6	THE ROLE OF CA²⁺ SIGNALLING IN THE DIFFERENTIATION OF EMBRYONIC STEM CELLS (ESCs) INTO CARDIOMYOCYTES	167
	<i>Dckzkc 'J c q . 'Y gplkg 'Y gk 'Uctcj 'GOY gdd . 'Cpft gy 'NOO kngt 'and 'Lkpdq' [w g</i>	
	INTRODUCTION	168
	METHODS TO INDUCE <i>IN VITRO</i> CARDIOMYOCYTE DIFFERENTIATION	169
	THE ROLE OF CA²⁺ SIGNALLING IN THE DIFFERENTIATION OF ESCs INTO CARDIOMYOCYTES	172
	Inositol 1,4,5-Trisphosphate Receptors (IP3Rs)	172
	L-Type Ca ²⁺ Channels (LTCCs) and Ryanodine Receptors (RyRs)	174
	Cluster of Differentiation 38 (CD38) and Cyclic Adenosine Diphosphate Ribose (cADPR)	175
	Store-Operated Ca ²⁺ Entry (SOCE)	176
	Transient Receptor Potential (TRP) Channels: TRPV1 and TRPC3	177
	Ca ²⁺ Clearance Mechanisms (SERCA and NCX)	177
	Calreticulin	178
	CONCLUSION AND FUTURE PERSPECTIVES	179
	CONFLICT OF INTEREST	180
	ACKNOWLEDGEMENTS	180
	REFERENCES	181
CHAPTER 7	REGENERATIVE CELL-BASED THERAPIES TO COMBAT NEURODEGENERATIVE DISORDERS	188
	<i>\ ctggp 'Co wn</i>	
	INTRODUCTION	188
	Neural Stem/Precursor Cells (NSPCs)	192
	Embryonic Stem Cells (ESCs)	194

Induced Pluripotent Stem Cells (iPSCs)	195
Induced Neural Progenitor Cells (iNPCs)	195
Limitations of Cell-based Therapies	197
CONCLUSION	199
CONFLICT OF INTEREST	199
ACKNOWLEDGEMENTS	199
REFERENCES	199
CHAPTER 8 STEM CELL TRANSPLANTATION: IS THIS THE FUTURE SOLUTION FOR PARKINSON'S DISEASE?	206
<i>Lq² Twd² p¹ cte² / Oqpvu² and Tgp² Ft wengt / Eq² f²</i>	
INTRODUCTION	206
Parkinson's Disease	207
Parkinson's Disease Treatment	208
Understanding the Graft in Basal Ganglia Circuitry	209
Some Controversial Facts about Basal Ganglia Models	210
Basal Ganglia Grafts	211
The Graft in PD Patients: The Past and the Current	211
<i>Adrenal Medulla</i>	211
Ventral Mesencephalon Tissue	213
Stem Cells	216
Other Graft Sources	220
Limitations	221
The Neurogenic Niche: Permissive or Not	222
The Central Nervous System Grafts: Are We Still Facing the Same Problems?	224
CONCLUSIONS	227
CONFLICT OF INTEREST	228
ACKNOWLEDGEMENTS	228
ABBREVIATIONS	228
REFERENCES	229
SUBJECT INDEX	263

PREFACE

Research in the rapidly emerging field of stem cells is playing a pivotal role in regenerative medicine. The first 3 chapters of this volume deal with mesenchymal stem cell research. In chapter 1, Wei Seong Toh presents the emerging role of mesenchymal stem cell (MSC) secretome as a new paradigm in treating cartilage regeneration. The study of MSC secretome allows a better mechanistic understanding of the role of MSCs in tissue repair and disease treatment.

Mauricio *et al.* describe a promising strategy for the optimization of hybrid systems through the association of biomaterials to dental pulp stem cells, in chapter 2. Dental pulp stem cells can be easily isolated from deciduous and definitive teeth. In chapter 3, Kan *et al.* describe the recent progress and the opportunities as well as challenges in MSC research.

Arteta *et al.*, in chapter 4, discuss current studies that underline the importance of liver progenitor cells (LPCs) for constructing bioartificial livers and as the source of cells for transplantation.

In the next chapter, Ward *et al.* present new exciting developments in cardiogenesis from bench-to bedside. They review the heart development in different organisms, supplemented with insights from stem cell biology and clinical studies, which will throw light on the development of effective stem cell treatments for myocardial infarction and other cardiac diseases. Yue *et al.*, in their chapter 6, present an overview of different Ca^{2+} signalling events in the differentiation of embryonic stem cells into cardiomyocytes.

The last two chapters deal with neurodegenerative diseases. Zareen Amtul, in Chapter 7, highlights the regenerative cell-based therapies that can be used to combat neurodegenerative disorders. In the last chapter, García-Montes and Drucker-Colín discuss in detail about the central role of stem cell transplantation to cure Parkinson's Disease. They discuss the current challenges in optimizing stem cell therapy for the treatment of Parkinson's disease.

We hope that the readers will enjoy the comprehensive reviews on new developments in stem cell and regenerative medicine research. We wish to thank the editorial staff of Bentham Science Publishers, particularly Dr. Faryal Sami, Mr. Shehzad Naqvi and Mr. Mahmood Alam for their constant help and support.

Prof. Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

&

Dr. Shazia Anjum
Department of Chemistry
Cholistan Institute of Desert Studies
The Islamia University of Bahawalpur
Pakistan

List of Contributors

- Aitor Benedicto** Department Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country, E-48940 Leioa, Spain
- Alister C. Ward** School of Medicine, Deakin University, Geelong, Australia
Centre for Molecular and Medical Research, Deakin University, Geelong, Australia
- Ana Colette Maurício** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
- Ana Rita Caseiro** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
CEMUC, Departamento de Engenharia Metalúrgica e Materiais, Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal
- Andrew L. Miller** Division of Life Science and State Key Laboratory of Molecular Neuroscience, HKUST, Clear Water Bay, Hong Kong, China
- Antonia Alvarez** Department Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country, E-48940 Leioa, Spain
- Baixia Hao** Division of Life Science and State Key Laboratory of Molecular Neuroscience, HKUST, Clear Water Bay, Hong Kong, China
- Beatriz Arteta** Department Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country, E-48940 Leioa, Spain
- Carla Mendonça** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
- Chen Kan** Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
- Daniel McCulloch** School of Medicine, Deakin University, Geelong, Australia
Centre for Molecular and Medical Research, Deakin University, Geelong, Australia
- Enrique Hilario** Department Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country, E-48940 Leioa, Spain
- Haimei Lu** Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China

- Inês Leal Reis** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
- Jianbo Yue** Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China
- Joana Marquez** Department Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country, E-48940 Leioa, Spain
- José Domingos Santos** CEMUC, Departamento de Engenharia Metalúrgica e Materiais, Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal
- José Rubén García- Montes** Departamento de Neurobiología funcional y de sistemas, Instituto Cajal. Madrid, España,
- José Miguel Campos** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
Escola Universitária Vasco da Gama (EUVG), Hospital Veterinário Universitário de Coimbra (HVUC), Av. José R. Sousa Fernandes, Campus Universitário – Bloco B, Lordemão, 3020-210 Coimbra, Portugal
- Lijun Chen** Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
- Lixin Kan** Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Department of Medical Laboratory Science, Bengbu Medical College, Bengbu, Street no., Bengbu, China
Department of Neurology, Northwestern University, Chicago, USA
- Luís Miguel Atayde** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
- René Drucker-Colín** Departamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, México
- Rui Alvites** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal

- Sarah E. Webb** Division of Life Science and State Key Laboratory of Molecular Neuroscience, HKUST, Clear Water Bay, Hong Kong, China
- Sheena Raju** Regenerative Medicine, Reliance Life Sciences Pvt Ltd, Mumbai, India
School of Medicine, Deakin University, Geelong, Australia
- Silvia Santos Pedrosa** Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal
Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
- Wei Seong Toh** Faculty of Dentistry, National University of Singapore, Singapore
Tissue Engineering Program, Life Sciences Institute, National University of Singapore, Singapore
- Wenjie Wei** Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China
- Yangyang Hu** Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
- Zareen Amtul** Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan

CHAPTER 1**The Emerging Role of Mesenchymal Stem Cell Secretome in Cartilage Regeneration****Wei Seong Toh****Faculty of Dentistry, National University of Singapore, Singapore**Tissue Engineering Program, Life Sciences Institute, National University of Singapore, Singapore*

Abstract: Articular cartilage has a limited capacity to repair following injury. As a result, cartilage injuries often progress to serious joint disorders such as osteoarthritis. Mesenchymal stem cells (MSCs) are currently being evaluated in clinical trials as the therapeutic cell source for treatment of cartilage lesions and osteoarthritis. In addition to their differentiation potential, it is widely accepted that the beneficial actions of MSCs can also be mediated by their secretome. Of note, it has been demonstrated that MSCs are able to secrete a broad range of trophic factors and matrix molecules in their secretome to modulate the injured tissue environment and direct regenerative processes including cell migration, proliferation and differentiation to mediate overall tissue regeneration. The study of MSC secretome not only allows a better mechanistic understanding of the role of MSCs in tissue repair and disease treatment, but also enables the potential development of the *next-generation*, ready-to-use, highly-amenable and ‘cell-free’ therapeutics for clinical application. In this chapter, we present the latest understanding of MSC secretome and its components as a new paradigm for the treatment of cartilage lesions and osteoarthritis.

Keywords: Cartilage, Exosomes, Extracellular vesicles, Immunomodulation, Mesenchymal stem cells, Osteoarthritis, Secretome, Tissue regeneration.

INTRODUCTION

Articular cartilage is a unique hypocellular, avascularized and aneural load-bearing tissue, supported by the underlying subchondral bone [1]. Due to the lack of vascularization, articular cartilage has a limited capacity for regeneration upon injury. Articular cartilage injuries have a high incidence and therefore a high socio-economic and healthcare impact that cannot be underestimated. In knee joint alone, ~60% of patients who underwent arthroscopy displayed cartilage lesions [2]. When left untreated, these lesions can lead to osteoarthritis (OA), an

* Corresponding author **Wei Seong Toh:** Faculty of Dentistry, National University of Singapore, 11 Lower Kent Ridge Road, Singapore 119083; Tel: +65 6779 5555 ext. 1619; Fax: +65 6778 5742; Email: dentohws@nus.edu.sg

inflammatory and degenerative joint disease characterized by the degradation of the articular cartilage, subchondral bone, meniscus, ligaments, and the formation of painful osteophytes. OA is the most common form of arthritis affecting numerous joints including the knee joint, hip joint, and the temporomandibular joint (TMJ), and is the leading cause of disability worldwide [3, 4].

Current treatment options for articular cartilage injuries include arthroscopic lavage and debridement, microfracture, osteochondral grafting, and autologous chondrocyte implantation (ACI) [2]. While there are tissue repair with symptomatic relief, most cartilage repair techniques lead to fibrocartilaginous tissue repair that lacks the structural organization and matrix composition of the native articular cartilage.

Stem cells represent a promising cell source for cartilage repair [5, 6]. Currently, stem cells are classified into embryonic or ‘pluripotent’ stem cells, and non-embryonic ‘somatic’, ‘adult’ or ‘tissue’ stem / progenitor cells [6]. Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo, and are defined by two distinct properties: pluripotency and unlimited self-renewal. They are able to differentiate into cell derivatives of the three primary germ layers including ectoderm, endoderm and mesoderm [7]. With advances in stem cell biology, personalized pluripotent stem cells, also known as induced pluripotent stem cells (iPSCs) can be derived from somatic cells through reprogramming using defined gene and protein factors [8]. Of note, several groups have reported differentiation of human ESCs and iPSCs to chondrocytes [9 - 12], and demonstrated the functional efficacy of these cells for cartilage repair in animal studies [13 - 16].

Adult stem / progenitor cells are undifferentiated multipotent cells present in various adult tissues as they contribute to the physiological cell turnover as well as to tissue repair. Among these adult stem cells, mesenchymal stromal/stem cells (MSCs) are the most extensively studied and used cell type in clinical trials and have been heralded as the next major development for treatment of tissue injuries and diseases (<http://www.clinicaltrials.gov>). Of note, MSCs are currently being evaluated in clinical trials for treatment of cartilage injuries and osteoarthritis (OA) [17, 18]. While it is clear that MSCs are able to differentiate *in vitro* into a variety of cell types including chondrocytes, osteoblasts and adipocytes, MSCs are increasingly being investigated and harnessed for their trophic functional abilities [6, 19]. This book chapter aims to discuss the role of MSCs in cartilage regeneration and to present the latest development of MSC secretome and its components as a new paradigm for treatment of cartilage injuries and osteoarthritis.

MESENCHYMAL STEM CELLS

Mesenchymal stromal/stem cells (MSCs) are multipotent adult stem cells capable of self-renewal and multi-lineage differentiation into osteoblasts, chondrocytes and adipocytes [20]. They are easily isolated from a wide variety of tissues including bone marrow, muscle, adipose tissue, blood, and synovium [21 - 23]. MSCs are isolated as a heterogeneous cell population and characterized by their ability to adhere to plastic, form colonies in colony-forming unit-fibroblast (CFU-F) assay, and differentiate into osteoblasts, chondrocytes and adipocytes [20, 24]. According to the minimal criteria defined by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT), MSCs are positive for cell surface markers CD73, CD90 and CD105, and negative for CD34, CD45, CD11b, CD14, CD19, CD79a and human leukocyte antigen (HLA)-DR surface molecules [25].

MESENCHYMAL STEM CELL-BASED THERAPIES FOR CARTILAGE REPAIR

Several MSC-based strategies for cartilage repair have been reported in animal [26] and clinical studies [17]. MSCs can be used in direct cell transplantation, and/or in combination with growth factors and scaffolds [26]. Direct transplantation of MSCs occur commonly in the form of fresh marrow or monolayer expanded and selected cells [27]. The use of fresh marrow or freshly isolated mononuclear cells is gaining interest due to their rapid availability without the need for cell expansion [28]. Furthermore, fresh marrow comprises not only MSCs but also accessory cells and growth factors.

However, in all above described cell-based strategies for cartilage repair, the culture conditions remains an issue, and there is currently poor standardization for the culture conditions and the number of cells needed for transplantation with respect to various sizes and types of cartilage lesions [29]. As with all cell-based therapies, there exist significant logistical and operational challenges associated with proper handling and cell storage to maintain the vitality and viability of the cells for transplantation [30]. With advances in proteomics, it is becoming clear that MSCs not only exhibits ability to differentiate into multiple lineages, but also secrete a broad spectrum of trophic factors in the secretome that are mediating various aspects and processes of tissue repair and regeneration [19] (Fig. 1). In the past decade, the investigation of MSC secretome has therefore gained much attention, with the interest to decipher the factor (s) mediating the biological activity of MSCs in tissue repair.

CHAPTER 2

The Potential Clinical Application of Mesenchymal Stem Cells from the Dental Pulp (DPSCs) for Bone Regeneration

Ana Rita Caseiro^{1,2,3,#}, Rui Alvites^{1,2,#}, Sílvia Santos Pedrosa^{1,2,#}, José Miguel Campos^{1,2,4}, Inês Leal Reis^{1,2}, José Domingos Santos³, Carla Mendonça^{1,2}, Luís Miguel Atayde^{1,2} and Ana Colette Maurício^{1,2,*}

¹ Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências, Tecnologias e Agroambiente (ICETA) da Universidade do Porto, Praça Gomes Teixeira, Apartado 55142, 4051-401, Porto, Portugal

² Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal

³ CEMUC, Departamento de Engenharia Metalúrgica e Materiais, Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal

⁴ Escola Universitária Vasco da Gama (EUVG), Hospital Veterinário Universitário de Coimbra (HVUC), Av. José R. Sousa Fernandes, Campus Universitário – Bloco B, Lordemão, 3020-210 Coimbra, Portugal

Abstract: The skeleton has the vital role of providing support and protection to all body organs, as well as to function as storage system for ions and other components essential to its homeostasis, also presenting essential function in the movement and posture of the individual. Bone fractures are a fairly common situation affecting individuals of all ages, but gain importance when concomitant pathologies are present or when the bone lesions' extension exceeds the tissues' intrinsic healing capabilities. As such, biomedical research has invested in unveiling adequate therapies to aid in those cases. The tissue engineering field has therefore evolved in the direction of developing biomaterials and scaffolds to structure, support and promote bone ingrowth, and in developing strategies to optimize these biomaterials *in vivo* performance, by including cell-based therapies and growth factors. Herein, we discuss one promising strategy for the optimization of these hybrid systems, through the association of biomaterials to a specific source of mesenchymal stem cells: the dental pulp stem cells. Dental pulp stem cells can be found in individuals of any age, and can be easily isolated from deciduous and definitive teeth, expanded and cryopreserved for further

* **Corresponding author Ana Colette Maurício:** Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Rua de Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal; Mobile: +351919071286; Tel: +351220428000; E-mails: ana.colette@hotmail.com, acmauricio@icbas.up.pt

These authors should be considered as first authors.

Atta-ur-Rahman & Shazia Anjum (Eds.)
All rights reserved-© 2017 Bentham Science Publishers

use. These cells are capable of differentiating towards multiple lineages, presenting great potential for osteo-differentiation. Dental pulp stem cells have been demonstrated to incorporate diverse biomaterial systems and promote mineral deposition both *in vitro* and *in vivo*, aiming at the reconstruction of osseous defects, in either experimental or clinical situations. The mesenchymal stem cells from the dental pulp can also be found and isolated from many species other than humans, granting them potential to be implemented not only in human medicine but also in veterinary care practices, and in regenerative strategies for other organs and tissues, such as dental reconstruction and nervous system regeneration.

Keywords: Adult teeth, Animal models, Biomaterials, Bone regeneration, Cell isolation, Cell sources, Ceramic biomaterials, Deciduous teeth, Dental cells, Dental pulp, Dental regeneration, Differentiation, Growth factors, *In vitro*, *In vivo*, Mesenchymal stem cells, Nerve regeneration, Stem cells, Tissue regeneration, Tooth.

INTRODUCTION

Nearly 30 years ago, Vacanti [1] described the transplantation of cells using bio-absorbable polymer matrices. That was the beginning of tissue engineering, then described as “an interdisciplinary field that applies principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function”. The fundamentals of tissue engineering are based on three major pillars: scaffolds, cells and regeneration factors, all deemed essential for the success of stem cells based therapies (Fig. 1) [2 - 4].

Stem cells are responsive undifferentiated cells with varying degrees of self-proliferation and differentiation plasticity. These characteristics makes stem cells attractive as tissue regeneration motors [5]. Although the number of stem cells is higher before birth, in the adult there are still several “niches” with a significant number of stem cells [6].

The stem cells “niches” in adults include the skin, adipose tissue, peripheral blood, bone marrow, pancreas, intestine, brain, hair follicles, and others, as well as in the dental pulp [7]. In this review we focus on dental pulp derived stem cell population. Dental stem cells (DPSCs) are one good alternative to other sources’ cells due to their easy collection from healthy donors and high proliferation and differentiation ability [8 - 11], with the advantage of being collect from both infants and adults, which are frequently subjected to dental orthodontic treatments that imply the removal of healthy teeth.




Fig. (1). The three pillars of tissue engineering – the biomaterial scaffolds that provide structure and a protective environment for the tissue regeneration; the cells that motor the regeneration itself; and the regeneration factors that promote and enhance cell growth and differentiation.

DENTAL STEM CELLS

Tooth Anatomy and the DPSCs Niche

Human teeth are an incredibly specialized organ composed of the crown (visible part that protrudes from the gingiva), the neck (the transition area), and the root (anchored to the alveolar bone). The external layer of the tooth is composed by enamel that covers and provides protection to the intermediate dentine part, and the inner pulp. Throughout life, human exhibit two series of teeth: the initial deciduous teeth (that start sequentially erupting around six months of age), followed by permanent / term or definitive teeth. The latest set of dentition starts developing from the tooth germ at approximately six years of age and sequentially ‘pushes out’ the deciduous dentition, in approximately six years (with exception for the 3rd molars or ‘wisdom teeth’ that, when present, arise around the twentieth year of age) [12].

Mesenchymal Stem Cells in Regenerative Medicine: The Challenges and the Opportunities

Chen Kan¹, Lijun Chen¹, Yangyang Hu¹, Haimei Lu¹ and Lixin Kan^{1,2,3,*}

¹ Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China

² Department of Medical Laboratory Science, Bengbu Medical College, Bengbu, Anhui, China

³ Department of Neurology, Northwestern University, Chicago, USA

Abstract: Regenerative medicine generally aims at re-establishing the normal functions by replacing the damaged body parts through stem cells or other biomedical approaches. The tremendous opportunities of mesenchymal stem cells (MSCs) in regenerative medicine have long been recognized. However, this potential “off-the-shelf” therapeutic product is still facing daunting challenges. In this chapter, we intend to update the recent progresses and highlight the opportunities and the key challenges in the field. Our discussion has direct implications for identifying new directions for the future basic research as well as clinical applications of MSCs.

Keywords: Autoimmune diseases, Bone and cartilage diseases, Cell surface markers, Cell therapy, Cell transplantation, Clinical trial, Degenerative diseases, Immunomodulation, Mesenchymal stem cells (MSCs), “Off-the-shelf” therapeutic product, Pre-clinical investigation, Regenerative medicine, Safety profile, Tissue repair, Tissue engineering, Translational applications.

INTRODUCTION

Regenerative medicine deals with the process of engineering, replacing, or regenerating human cells, tissues or organs to restore or establish normal function. Regenerative medicine, in its broad sense, is not a new medical discipline, since the first successful bone graft (bone from a dog’s skull used to repair defect in human cranium) documented by van Meenerenin in 1668, the first thyroid transplant was performed by the Swiss surgeon Kocher in 1883, and the first

* Corresponding author Lixin Kan: School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China; Department of Medical Laboratory Science, Bengbu Medical College, Bengbu, Anhui, China; Department of Neurology, Northwestern University, Chicago, USA; Tel: 001-312-503-2791; Fax: 001-312-503-2793; E-mail: l-kan@northwestern.edu

corneal transplant was performed by Zirm in 1906. However, the term of “regenerative medicine” was coined much later by Kaiser in 1992 [1].

The first multipotent adult stem cell population, the hematopoietic stem cell (HSC), which gives rise to all the blood cells, was discovered in the 1950s. Subsequent investigations, in the 1960s -1970s, from Friedenstein and colleagues found that bone marrow also contains non-hematopoietic clonogenic stromal cell population [2 - 4], referred to as colony-forming unit-fibroblasts (CFU-F). These studies revealed the plasticity of these marrow cells, *i.e.*, these cells possess the multipotent properties of adult stem cells. For this reason, these cells were later called mesenchymal stem cells (MSCs) [5, 6].

Confusingly, there are many slightly different terms or definitions, such as mesenchymal stromal cells (MSCs) [7], multipotent adult progenitor cells (MAPCs) [7], multipotent adult stem cells (MASCs) [8], multilineage progenitor cells (MLPC) [9] and skeletal stem cells (SSCs) [10], that presumably refer to similar, if not exactly the same cell population [11], and there are also other clearly distinct MSC subpopulations or MSC-like cells, such as very small embryonic-like (VSEL) stem cells [12, 13], multilineage-differentiating stress enduring (Muse) cells [14] and unrestricted somatic stem cells (USSC) [15] that are presumably with unique cell surface markers and differential potentialities. All these cause a great deal of controversies.

Nevertheless, since their original description, the presence of MSCs or MSC-like cells has been proven in almost all adult tissues such as adipose tissue [16, 17], muscle [18], peripheral blood [19], lung [20], heart [21], corneal stroma [22], dental pulp [23], placenta [24], endometrium [25], amniotic membrane [26], and Wharton’s jelly [27]. More importantly, this adult stem cell population possesses many desirable features, such as easy accessibility without any significant ethic concern, excellent safety profile (non-tumorigenic and non- or low-immunogenic), ability to exert trophic effects, self-renewal and multipotent differentiation, anti-apoptotic and immunomodulatory effects, and capacity for migration to the injury site, *i.e.*, homing [28], and participating in regeneration in a variety of tissues (Table 1). It is no wonder that the translational potential of cells was almost immediately recognized, especially for regenerative medicine.

Recent years witnessed the incredible progression and transformation of regenerative medicine, which mainly reflects the tremendous advances in the stem cell field. In fact, armed with MSCs, regenerative medicine is now unquestionably an active branch of translational research that could offer solutions and hope for people who have conditions that are currently beyond repair. The typical approaches of modern regenerative medicine include: 1) the injection of stem cells

or progenitor cells (cell therapies), 2) the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy), and 3) transplantation of *in vitro* grown organs and tissues (tissue engineering).

Table 1. Advantages and disadvantages of the different types of stem cells.

Stem cells	Advantages	Disadvantages	References
embryonic stem cells(ES)	pluripotent, relatively easy to propagate	ethical concerns, ability to form tumors including teratoma	[34, 35]
induced pluripotent stem cells (iPSC)	Similar to ES but less controversial, no ethical concerns	low efficiency, genomic insertion, incomplete reprogramming	[36, 37]
mesenchymal stem cells(MSC)	easy accessibility, no ethic concern, excellent safety profile, trophic effects, multipotent, anti-apoptotic, immunomodulatory, homing	heterogeneous, long-term expansion may cause phenotypical changes and senescence	[38 - 40]

The unique features of MSCs and the enormous unmet needs of regenerative medicine strongly justified the tremendous worldwide effects that have devoted to realize the potentials of MSCs for treatment of a variety of different clinical disorders (see Table 2 for the ongoing clinical trials). In fact, the scope of the opportunities, including basic researches [29], translational researches [30] and clinical applications [31], are overwhelmingly broad to be covered at a reasonable depth. Therefore, in this chapter, we will have to focus only on the selected subtopic, *i.e.*, 1) perspective of MSCs in regenerative medicine, 2) the phenotypical characteristics of MSCs and the related challenges, and 3) the clinical opportunities and the challenges. In this section, we focus only on regenerative medicine, especially the highly impact disorders.

On the other hand, MSCs are also facing daunting challenges despite decades of intense research and many ongoing clinical trials [32, 33] (Table 2). In fact, the practical and theoretical challenges that have bottlenecked the field so far are almost as great as the opportunities, if not more overwhelmingly. Therefore, similarly, we will focus only on the most important challenges.

Overall, our main aims of this chapter are to outline the current understanding of the selected field, update the recent progress and highlight the opportunities as well as the key challenges. Hopefully, our discussion will help clarify the confusion, put the key issues in right perspective and identify new fruitful directions for the future research as well as clinical applications.

Liver Regeneration: An update on the Role of Non-Parenchymal Cells

Beatriz Arteta*, Antonia Alvarez, Joana Marquez, Aitor Benedicto and Enrique Hilario

Department of Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country, E-48940 Leioa, Spain

Abstract: Many advances have been made during last years in the field of liver regeneration. Current studies underline the importance of liver progenitor cells (LPCs) as one of the sources for constructing bioartificial livers (BAL) and as source of cells for transplantation. However, the liver microenvironment is also formed by non-parenchymal cells (NPCs) that interact with LPCs and parenchymal cells during liver regeneration. Recent advances in liver tissue engineering have shown the importance of NPCs in extracorporeal systems, such as bioreactors for BAL or in several systems of 3D culture in combination with either hepatocytes, hepatoblast or LPCs. A precise knowledge of the functional role and the relationships between the diverse liver cell types is of great importance in the development of a liver organoid. Thus, this review focuses on the role of NPCs during liver regeneration in regard to their relationship with LPCs, and their potential use in 3D and extracorporeal systems in order to improve their efficacy and thus, their potential to be in the clinical setting.

Keywords: 3D co-culture, Bioartificial liver, Bioreactor, Extracellular matrix, Hepatic stellate cells, Hepatic stem cells, Hepatocytes, Kupffer cells, Liver progenitor cells, Liver regeneration, Liver sinusoidal endothelial cells, Non-parenchymal cells.

INTRODUCTION

The liver is a complex organ with an impressive regenerative potential to recover normal liver function after injury. Even though hepatocytes are the main contributors to normal cell turnover and to liver regeneration (LR) after partial hepatectomy (PH), when the regenerative capacity of the liver is impaired, liver progenitor cells (LPCs) become activated [1, 2], proliferate and differentiate.

* **Corresponding author Beatriz Arteta:** Department of Cell Biology and Histology, School of Medicine and Enfermery, University of Basque Country. E-48940 Leioa, Spain; Tel: +34 94612880; Fax: +34 946013266; E-mail: beatriz.arteta@ehu.es

LPCs consist in a bipotential progenitor cells which differentiate into hepatocytes as well as into cholangiocytes [3] depending on the signals they receive from other liver cells present in the liver microenvironment, including liver sinusoidal endothelial cells (LSECs), liver macrophages, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and also by signals from the extracellular matrix (ECM) they produce [2]. In fact, activating signals from such various sources can easily reach the LPCs in liver diseases of diverse etiologies [4, 5].

The liver microenvironment is a complex milieu composed of different cell types which actively interact with each other in a well-orchestrated cellular and molecular cross-talk in the different liver cell compartments [6]. Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF- α) [7], Osteopontin, Transforming Growth Factor beta (TGF β) [8], TNF-like weak inducer of apoptosis (TWEAK) [9], Hepatocyte Growth Factor (HGF) [10] are just a few examples of cytokines and growth factors produced by the liver cells, capable of promoting LPC-mediated regeneration [11]. The joint action of these soluble factors together with cell-cell interaction and with the surrounding ECM will decide the fate of LPCs either into mature hepatocytes or cholangiocytes.

Nowadays, very active research is being carried out concerning the potential use of NPCs and LPCs in the construction of bioartificial livers and 3D co-cultures systems for clinical application. As a result many *in vitro* and *in vivo* models are being developed to look deep into the mechanisms of liver injury and generate new and improved models in order to apply them on a daily basis-clinical setting. Even though this active investigation has led to a significant increase in our knowledge in the last decade, more research is needed to comprehend the intricate network of cells and molecules that form the liver microenvironment.

Non Parenchymal Cells within the Liver Microenvironment

The liver is mainly formed by parenchymal cells, namely hepatocytes, and NPCs consisting in LSECs [12], KCs [13], HSCs [14], lymphocytes and biliary epithelial cells [15, 16] (Fig. 1). Additionally, even though the liver contains less proportion of ECM compared to other organs, liver ECM plays an important role in maintaining the differentiated phenotype of hepatocytes and NPCs [17, 18]. In this review we will focus our attention on the main NPCs leaving out the lymphocytes for further studies due to their complexity in function and cell components, and also the biliary component, which has been already extensively reviewed [19, 20].

The endothelial cells lining the hepatic sinusoids differ in many aspects from other endothelial cells. They are fenestrated and do not possess a regular basement membrane. Additionally, LSECs express multiple endocytic receptors and surface

molecules which endow them with the ability to regulate the homeostasis and the immunological function of the liver [21 - 23].




Fig. (1). Schematic view of the liver sinusoids and portal triad. Liver progenitor cells (LPCs) are located in the canal of Hering in the area of the bile ducts. LPCs are in close vicinity with nonparenchymal cells (NPCs) which include liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs), hepatic stellate cells (HSCs) and lymphocytes (NK cells, NKT cells, neutrophils, among others).

Liver macrophages/Kupffer cells lie in the hepatic sinusoids in close contact with LSECs and represent the bigger population of resident macrophages of the body [24]. They stand as a first line of defense against circulating pathogens and are able to initiate an inflammatory response in the liver by releasing multiple mediators involved in pathological processes [25].

The HSCs are resident perisinusoidal cells which possess a key role in normal and injured liver. HSCs take part in the diseases causing chronic liver injury by its contribution to portal hypertension, increased fibrogenesis, amplification of inflammation and altered matrix degradation [26]. These myofibroblast-like liver non-parenchymal cells mediate the ECM deposition and remodeling in the

Cardiogenesis and Repair: Insights from Development and Clinical Trials

Sheena Raju^{1,2}, Daniel McCulloch^{2,3}, Alister C. Ward^{2,3,*} and Chandra Viswanathan¹

¹ Regenerative Medicine, Reliance Life Sciences Pvt Ltd, Mumbai, India

² School of Medicine, Deakin University, Geelong, Victoria, Australia

³ Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria, Australia

Abstract: Cardiovascular diseases are major contributors to global mortality. Myocardial infarction represents a significant complication of one such disease that affects a very large population worldwide, with the ischemic region and the resultant scar tissue generated reducing cardiac function and becoming a focus for recurrent infarctions. Several stem cell therapy approaches aimed at regenerating the non-functional myocardium have emerged using multipotent and pluripotent stem cells. However, many of the pre-clinical and clinical trials have not yielded the anticipated outcomes, and so different strategies are now being explored to achieve regeneration. The failure of these stem cell therapies may be partially attributable to the dearth of information on human cardiac developmental and regenerative pathways. However, numerous studies have investigated cardiogenesis and heart regeneration in model organisms, which have provided considerable insights into the processes of cardiac development, and other studies on the differentiation of pluripotent stem cells have largely corroborated these findings. Here we review heart development in different organisms, supplemented with insights from stem cell biology and clinical studies, which will underpin the development of effective stem cell treatments for myocardial infarction and other cardiac insults.

Keywords: Cardiogenesis, Chicken, CVD, EPC, Fruit fly, HSC, Human, Mesoderm, Mouse, MSC, Myocardial infarct, Regeneration, Stem cells, Toad, Zebrafish.

INTRODUCTION

Cardiovascular diseases (CVDs) – including coronary heart disease, ischemic heart disease, cardiomyopathies, cardiac dysrhythmias, cerebrovascular disease,

* **Corresponding author Alister C. Ward:** School of Medicine and Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria 3216, Australia; Tel: +61 3 52272041; E-mail: alister.ward@deakin.edu.au

peripheral arterial disease, rheumatic heart disease, congenital heart disease, valvular heart disease, deep vein thrombosis and pulmonary embolisms – are major causes of mortality worldwide. In 2008, CVDs were the leading cause of mortality due to non-communicable diseases globally (17 million deaths/57 million total) [1], while in the USA the deaths attributable to non-congenital CVDs were 236.1 per 1000 in 2009. CVDs also affect the quality of life and productivity of affected individuals [2]. Due to these glaring statistics, extensive research has been directed towards understanding CVDs and developing effective treatments.

Ischemic heart disease (IHD) is one of the major CVDs in terms of morbidity and mortality. IHD is caused by a reduction of blood flow due to atheroma, thrombosis or spasm, or decreased blood oxygenation due to anemia, carboxy-hemoglobinemia and other causes. One of the main complications of ischemic heart disease is myocardial infarction (MI), a consequence of ischemia-induced cardiomyocyte death, which typically occurs due to the rupture or erosion of a coronary artery plaque. MIs initially affect the sub-endocardial myocardium, but prolonged ischemia can extend this to the sub-epicardial myocardium. Complications arising due to MI include heart failure, myocardial rupture, aneurysmal dilatation, ventricular septal defect, mitral regurgitation, cardiac arrhythmias, atrial fibrillation, conduction disturbances and post MI pericarditis. It was estimated that in the USA alone the number of individuals who have suffered MI was 7.6 million and heart failure was 5.1 million [2]. Following a MI episode a cascade of events occurs in the myocardium leading to activation of repair mechanisms, including within non-infarcted myocardium. This is principally mediated by myofibroblasts that proliferate in response to tumor growth factor β (TGF β), leading to formation of scar tissue due to the expression of type I and fibrillar collagen [3 - 5]. The process also involves the activation of matrix metalloproteinases (MMPs) that facilitate the migration of circulatory inflammatory cells such as neutrophils and monocytes to the infarct site, where they participate in the phagocytosis and proteolytic digestion of infarcted tissue [4, 6]. The current treatment of MI involves revascularization, therapeutic vasodilation and surgical interventions [7]. The management of this condition also includes changes in lifestyle to reduce risk factors associated with further episodes. These existing approaches provide relief from symptoms and survival benefits, but fail to restore the damaged myocardial tissue to a healthy and fully functional state.

Regenerative medicine represents the means to effectively treat CVDs, providing the ability to generate new myocardial tissue *in situ*. However, to do so effectively requires a detailed understanding of cardiogenesis and cardiac stem cells. A variety of experimental systems, including both model organisms and cultured

stem cells, continue to provide important information in this regard. This Chapter reviews these experimental systems, their application to studying cardiogenesis and cardiac repair, as well as the essential lessons learned for clinical applications.

MODEL ORGANISMS IN THE STUDY OF CARDIOGENESIS

Introduction to Cardiac Development

A wide variety of model organisms have been studied to understand the mechanisms involved in embryonic development, which has provided comprehensive insights with relevance to human development. For cardiogenesis, these include invertebrate species like insects, such as fruit fly (*Drosophila melanogaster*) [8 - 10], along with several vertebrate species, most notably zebrafish (*Danio rerio*) [11 - 18], toad (*Xenopus* sp.) [19], chicken (*Gallus gallus*) [20 - 32], and mouse (*Mus musculus*) [33, 34]. Collectively, studies in those model organisms have revealed a high degree of conservation of the mechanisms involved in cardiogenesis during evolution, and allowed the dissection of the chronology, morphogenesis, cellular ontogeny and molecular pathways underlying this process.

Fruit Fly Cardiac Development

Heart tube development in fruit fly has provided a unique model system for the study of cardiogenesis. Its simplicity has facilitated the identification of the key factors involved, while its accessibility has meant that the morphological events during heart formation have been able to be dissected at the single cell level.

The heart or ‘dorsal vessel’ in the fruit fly consists of two types of cells, namely the cardioblasts and pericardial cells, each of which develop from cardiac progenitors in the lateral mesoderm as longitudinal rows (Fig. **1A**). The cardioblasts develop segmentally and migrate to the midline to form the lumen of the dorsal vessel (Fig. **1B**). The fully-developed adult heart consists of this simple linear tube, divided into anterior and posterior chambers, in which the contractile cardiomyocytes are derived from the cardioblasts and are flanked by pericardial cells (Fig. **1C**) [35, 36].

The molecular events co-ordinating the regulated movements of cardiomyocytes in fruit fly are highly conserved, with their vertebrate homologs shown to be involved in cardiogenic specification and heart development (Table **1**). The *tinman* gene, encoding a homolog of NKX2.5, was found to be expressed in the dorsal tip of the mesoderm, which contains the cardiac precursor cells and continues to be expressed in the heart progenitors until late embryonic stages [37]. The induction of *tinman* requires expression of *twist* in the presumptive

CHAPTER 6

The Role of Ca²⁺ Signalling in the Differentiation of Embryonic Stem Cells (ESCs) into Cardiomyocytes

Baixia Hao¹, Wenjie Wei², Sarah E. Webb¹, Andrew L. Miller¹ and Jianbo Yue^{2,*}

¹ Division of Life Science and State Key Laboratory of Molecular Neuroscience, HKUST, Clear Water Bay, Hong Kong, China

² Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China

Abstract: Embryonic stem cells (ESCs) possess the capability of self-renewal and pluripotency. They can propagate indefinitely and differentiate into any type of cell derived from the endoderm, mesoderm and ectoderm. This makes them ideal for basic research as well as for the development of treatments and cures for a variety of different diseases. This is especially so for developing methods to treat heart disease, where they might be used for screening cardiovascular drugs or for improving transplantation procedures in a clinical application. Thus, understanding the pathways involved in the regulation of the differentiation of ESCs into cardiomyocytes and developing efficient and reliable methods to induce differentiation, are key to the progress of cardiac research. In this chapter, the main methods currently used to induce the differentiation of ESCs into cardiomyocytes are reviewed. These include the use of embryoid body (EB)-dependent cultures, two-dimensional (2D) monolayer cultures, and the co-culture of human ESCs (and iPSCs) with mouse visceral endoderm-like stromal (END-2) cells. We also present a broad overview of the different Ca²⁺ signalling events that are known to occur during the differentiation of ESCs into cardiomyocytes. These include: 1) Ca²⁺ mobilization from the endoplasmic reticulum (ER)/sarcoplasmic reticulum (SR) mediated by inositol 1,4,5-trisphosphate receptors (IP₃Rs) and ryanodine receptors (RyRs); 2) the possible involvement of cluster of differentiation 38 (CD38)/cyclic adenosine diphosphate ribose (cADPR) signalling; and 3) the influx of Ca²⁺ from the extracellular medium *via* L-type Ca²⁺ channels (LTCCs), store-operated Ca²⁺ entry (SOCE), transient receptor potential vanilloid 1 (TRPV1), and transient receptor potential canonical 3 (TRPC3) channels. Moreover, the role of the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA), Na⁺/Ca²⁺ exchanger (NCX) and calreticulin in regulating cardiomyocyte differentiation by maintaining Ca²⁺ homeostasis is also described. Understanding how Ca²⁺ signalling regulates the differentiation of ESCs into cardiomyocytes might provide valuable clues for the development of efficacious treatments for cardiovascular disease.

* **Corresponding author Jianbo Yue:** Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China; Tel: 852-3442-2812; Fax: 852-34420549; Email: jianbyue@cityu.edu.hk

Atta-ur-Rahman & Shazia Anjum (Eds.)
All rights reserved-© 2017 Bentham Science Publishers

Keywords: Ca²⁺ signalling, Calreticulin, Cardiomyocyte differentiation, CD38, Co-culture, Embryoid body, Embryonic stem cells, Heart disease, IP₃Rs, LTCCs, Monolayer culture, NCX, Orai1, Pluripotency, RyRs, Self-renewal, SERCA, SOCE, Spontaneous beating, STIM1, Synchronous beating, TRPC3, TRPV1.

INTRODUCTION

Heart disease, also called cardiovascular disease, is one of the leading causes of death in the world today. Because the human heart has a very limited capacity for self-repair, there are few effective treatments for congestive heart failure, congenital heart disease, and heart attacks due to atherosclerosis [1, 2]. In the most severe cases, the only option is a heart transplant. However, there is a paucity of healthy organs from recently deceased donors that are suitable for transplantation and various post-operative complications can occur, such as organ rejection [3]. Therefore, it is imperative to develop alternative methods for treating heart disease. When embryonic stem cells (ESCs) were first isolated and characterized, and their potential for cell therapy was recognized, a lot of effort was subsequently spent in developing methods for treating cardiovascular disease *via* cell replacement. ESCs are cells in the inner cell mass (ICM) of blastocysts that possess the capacity of self-renewal and pluripotency [4, 5]. Thus, ESCs can divide in an unlimited manner and can differentiate into all the derivatives of the three germ layers (*i.e.*, the ectoderm, mesoderm and endoderm) [6, 7]. This means that ESCs hold great potential in cell therapy for the treatment of various kinds of diseases, and in heart disease in particular. Following the discovery of ESCs, the conversion of already-differentiated cells into so-called induced pluripotent stem cells (iPSCs) was made possible. For example, mouse and human fibroblasts were converted to iPSCs *via* the introduction of just four transcription factors, Oct3/4, Sox2, C-myc and Klf4 [8, 9], and human somatic cells were dedifferentiated into iPSCs with a different combination of factors, *i.e.*, Oct4, Sox2, NANOG and LIN28 [10]. iPSCs exhibit the same morphology and growth properties as ESCs, which makes them very useful in drug discovery, disease modelling and transplantation medicine. However, there are a number of major obstacles in the application of both ESCs and iPSCs in cell therapy. These include how the proliferation of transplanted cells might be controlled and how functional specifically-differentiated cardiomyocytes might be stably obtained. Therefore, a better understanding of the cellular and molecular mechanisms involved in the regulation of ESC and iPSC differentiation into cardiomyocytes, and the development of new methods of differentiation, are required before cells can be used for cardiovascular drug discovery and ultimately for the treatment of heart disease.

Similar to the *in vivo* heart development of vertebrate embryos, the differentiation of ESCs into cardiomyocytes is a multistep process, which is regulated by various signalling pathways, including the BMP/SMAD, Wnt, FGF/FGFR, and Notch/RBP-J pathways [11 - 15]. Following the identification of these regulatory mechanisms, a variety of cardiomyocyte differentiation protocols were developed to specifically generate nodal, atrial, or ventricular-like cells. In addition, Ca^{2+} is known to act as an important second messenger in many cellular activities in cardiomyocytes, including excitation-contraction (EC) coupling and cell viability [16]. Accumulating evidence indicates that Ca^{2+} signalling also plays a key role in regulating the differentiation of ESCs into cardiomyocytes [17 - 20]. In this chapter, we review the methods currently used to induce the differentiation of cardiomyocytes from ESCs as well as the role of Ca^{2+} signalling in this process.

METHODS TO INDUCE *IN VITRO* CARDIOMYOCYTE DIFFERENTIATION

ESCs provide a viable system for generating cardiomyocytes *in vitro* and thus facilitate the study of cardiogenesis with genetic manipulation or pharmacological treatment [21]. In order to be applied effectively in drug screens and cardiovascular disease modelling and therapy, functionally mature cardiomyocytes need to be generated in large numbers. Currently, there are three main methods used for inducing the differentiation of ESCs into cardiomyocytes: (1) embryoid body (EB)-dependent culture; (2) two-dimensional (2D) monolayer culture; and (3) co-culture of ESCs with mouse visceral endoderm-like stromal (END-2) cells [22, 23]. The differentiation state of cardiomyocytes obtained *via* these methods can be verified by analyzing the expression of cardiomyocyte-specific markers *via* RT-PCR and immunohistochemistry; by determining the sarcomeric organization of the myofibrils in these cells; by measuring their Ca^{2+} handling signature; and by measuring their electrophysiological properties to determine if they show the distinct action potential phenotypes of nodal, atrial, and ventricular-like cells (Fig. 1). In addition, the percentage of spontaneously beating cells and the beating frequency at early stages, as well as the presence of synchronous beating at later stages, are used as a measure of successful cardiomyocyte differentiation [22, 24]. The development of synchronous beating is associated with the formation of gap junctions; thus, the expression of the gap junction protein connexin 43, is also used as a means to determine the differentiation state of cardiomyocytes [25].

EB-dependent differentiation involves the 3D suspension culture of EBs, and recapitulates to a certain extent the normal growth environment of these cells by providing similar temporal and spatial cues that might occur during early embryogenesis. Using this method, cells derived from all three germ layers, including cardiomyocytes, can be generated [26]. During the formation of

Regenerative Cell-Based Therapies to Combat Neurodegenerative Disorders

Zareen Amtul*

Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan

Abstract: This chapter is a brief overview of the burden of neurodegenerative diseases, notably Alzheimer's disease, on society, the short falls of current drug therapies and emphasis on the reasons to increase our efforts in developing regenerative medicine-based stem cell therapeutics. The chapter further provides caution on unsettled translational concerns that are necessary to settle before proceeding with this innovative treatment to the clinic, in addition to highlighting the promising basic strides made in stem cell therapy of neurological disorders.

Keywords: Alzheimer's disease, Amyotrophic lateral sclerosis, Cell-based therapy, Embryonic stem cells, Epilepsy, Huntington's disease, Induced neural progenitor cells, Induced pluripotent stem cells, Neural stem cells, Neurodegenerative disease, Parkinson's disease, Regenerative therapy, Spinal muscular atrophy, Transplantation.

INTRODUCTION

Approximately fifty million people around the world are affected by devastating neurodegenerative disorders that cost society in physician visits, hospitalization, medication, home care, and loss of productivity over 600 billion USD/year [1 - 4]. With the rise in life expectancy and aging population, the occurrence of age-related neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease, Huntington's diseases, amyotrophic lateral sclerosis, multiple sclerosis, Friedreich's ataxia and lysosomal storage disorders (for example Batters disease) is predicted to increase inexorably with enormous economic and human costs. Ironically, these neurodegenerative diseases lack effective treatment options for patients.

* **Corresponding author Zareen Amtul:** Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan; Tel: 1-5196853845; E-mail: zareen.amtul@gmail.com

Alzheimer's disease, for instance a progressive neurodegenerative ailment, is the frequent reason of age-related dementia and in the U. S. alone affects over 5 million people [5]. Over 95% of the cases of multifactorial Alzheimer's disease are sporadic in nature. Clinically Alzheimer's disease gradually impairs cognition, ability to learn, and the performance of daily activities. Pathology of Alzheimer's disease includes depletion of large cortical cholinergic projection neurons, deposition of the extracellular amyloid β -peptide containing plaques (in brain parenchyma and blood vessels) [4, 6] intracellular neurofibrillary tangles, neuroinflammation, vascular impairment and synaptic and neuronal degeneration.

All amyloid disorders share compromised proteostasis as one of the key features (amyloidosis refers to the abnormal protein folding and aggregation of amyloidogenic proteins) that result due to the formation of insoluble aggregates. Just like amyloid plaques and neurofibrillary tangles are the misfolded protein aggregates in Alzheimer's disease, mutated superoxide dismutase is in amyotrophic lateral sclerosis [7], huntingtin and α -synuclein are in Huntington's disease and Parkinson's disease [6, 8], respectively. The aggregation process can be caused by the overproduction or poor clearance of these amyloidogenic proteins. Several reports suggest that in Alzheimer's disease, Parkinson's disease, and Prion disease, amyloid oligomers are the most toxic species rather than the insoluble fibrillar species [7, 9 - 11]. The particular amyloidogenic proteins that assemble and differ among amyloid disorders but they all share identical structural motifs. These structural features are used to target amyloidogenic proteins for therapeutic purposes.

Although a variety of drugs for proteostasis can relieve some of the symptoms associated with these ailments but largely these drugs provide only moderate and temporary relief to the sufferers. As a matter of fact, due to the strong faith in the Amyloid Cascade Hypothesis, the bulk of Alzheimer's disease research during the last decades has been $A\beta$ -based, which is unfortunately not supported by the failure of late-stage clinical trials [12 - 14]. Clinical trials on prodromal familial Alzheimer's disease cases began with the rationale that amyloid β -peptide triggers the disease and hence initiation of the $A\beta$ immunotherapies, several years before any clinical symptoms of the disease appear, would be effective. So far, all efforts to develop medications that aim $A\beta$ or other pathogenic pathways in sporadic cases of Alzheimer's disease have not been successful in late-stage clinical settings, with the very latest example is solanezumab by Eli Lilly pharmaceutical company [12, 15]. Several promising therapeutic candidates were supposed to be revolutionary medicines but have been unsuccessful in current trials on human (*reviewed in* [12]). Presently there is neither a cure nor an effective prevention for many of these diseases. Plausibly, a viable treatment for Alzheimer's disease has been to boost the production of cerebral acetylcholine neurotransmitter to

augment the loss of cholinergic neurons [16], however, this is not a curative measure either.

It has been challenging to learn about the cell biology of human neurodegenerative diseases until recently. Stem cell technology; such as neural stem cells (NSCs), mesenchymal stem cells (MSCs) [17], human embryonic stem cells (hESCs), pluripotent stem cells or induced pluripotent stem cell-derived neural cells (iPSCs) [18] that are differentiated into diverse types of specific neural and glial phenotypes have become an exceptionally appealing strategy, over the last couple of decades, to study and intervene neurodegenerative disorders [19, 20]. Neural cells have been successfully produced in the brain using both mesenchymal and neural stem cell transplantation and even *via* systemic injection of small molecular compounds [21]. Next to stimulating enthusiasm in developing therapeutics for neurodegenerative diseases, cell-replacement therapies also help to interpret the typical roles of neural genes in both neurodegenerative conditions as well as in neural development. Stem cells research seems to be an ideal translational therapy to progress into an effective treatment for patients suffering from Alzheimer's disease, Parkinson's disease, Huntington's disease [22, 23], spinal muscular atrophy [24] and amyotrophic lateral sclerosis [25, 26] (Table 1). In fact, treatment trials for amyotrophic lateral sclerosis, based on stem cell therapy have already been permitted by US Food and Drug Administration [27, 28].

Table 1. Cell based therapies applied in Parkinson's disease, amyotrophic lateral sclerosis, epilepsy, Alzheimer's disease and spinal muscular atrophy.

Donor cells	Model	Graft/Injection site	Therapeutic outcome	Possible mechanism	Ref.
Fetal DA neurons (mouse)	6-OHDA rat	-	Reduced apomorphine-induced rotation	-	[62]
Embryonic NSC (human)	6-OHDA macaque	-	Lowered Gomez-Mancilla dyskinesia score	-	[63]
Embryonic DA neurons (rate)	6-OHDA rat	-	Improved survival, reinnervation, behavioral recovery	Direct communication between DA neurons and FGF-2	[64]
Mesenchymal stromal cells	ALS human	-	Minor improvement	-	[65]

Stem Cell Transplantation: Is this the Future Solution for Parkinson's Disease?

José Rubén García- Montes¹ and René Drucker- Colín^{2,*}

¹ Departamento de Neurobiología funcional y de sistemas, Instituto Cajal. Madrid, España

² Departamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México Ciudad de México, México

Abstract: Significant effort in the past three decades has been dedicated to the concept of restoring normal neurological functions through stem cell transplants, in devastating neurodegenerative diseases including Parkinson's disease. The aim of this chapter is to present an objective and up-to-date progress in this field. Specifically, the successes as well as the failures and the lessons learned from these outcomes towards further achievements in regenerative therapy are discussed. We build an easily understandable progression from basics to more complex issues and the current challenges in optimizing stem cell therapy in treatment of Parkinson's disease.

Keywords: Basal ganglia, Chromaffins, Cell replacement, Grafts, Parkinson's Disease, Stem cells.

INTRODUCTION

Parkinson's Disease (PD) is the second most frequent neurodegenerative disease after Alzheimer's disease [1]. Epidemiological studies have calculated that 1-3% of 60-year-old people is affected with PD and it is predicted that this population will be doubled in 2030 [2]. In coincidence with tau pathologies, PD increases with age, and may affect up to a 9.3% in ages between 65 to 75, males being the most affected group [3]. Clinical motor symptoms of PD are directly associated with the degeneration of dopaminergic (DAergic) neurons in the *Substantia Nigra pars compacta* (SNpc) and are correlated with the appearance of intra-cytoplasmic inclusions called Lewy bodies (LBs) [4, 5]. Usually a patient diagnosed with this pathology becomes clinically detectable as a consequence of a 30% of dopamine (DA) deficit in the striatum. The decreased number of DAergic neurons in the

* Corresponding author René Drucker-Colín: Departamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Apdo. Postal 70-600, 04360 Ciudad de México, Mexico; Phone: (52-55) 5550-0064; E-mail: drucker@unam.mx

SNpc, discovered by Ehringer and Hornykiewicz in PD patients could summarize the last 50 years of research, since these studies provided the cue to treat PD. After Cotzias demonstrated that Levodopa (L-DOPA) restores the locomotion in PD patients in the 60's [6], there was no other successful procedure to restore dopamine until the adrenal medulla (AM) cell transplantation in PD patients in the early 80's [7, 8]. The revolutionary idea opened the possibility to treat neurodegenerative diseases such as Alzheimer disease and Parkinson's disease. After the initial grafts performed in humans, many cells have since been tested to restore the SNpc [8, 9]. It has therefore become increasingly important to understand the mechanisms through which these cells cause repair in PD as well as the specificities of the host zone. At present there are many questions on hold and new technologies such as neuro navigators, cell sorting techniques, PET Scans, better resonators, etc. have been developed to help improve implants and selectively restore DAergic neurons. Despite all these efforts, there still remain many unraveled questions about the necessary modifications required to improve the results of grafts when PD appears [10, 11]. Understanding changes induced by loss of DA in the striatum is vital to determine how to increase bioavailability of grafted cells. Currently there are new strategies to unmask the complex function of the striatum [12, 13]. Common questions such as does grafting restore normal activity of the neural circuits? Does graft life correspond to the clinical improvement? How can we avoid the damage caused by alpha synuclein in the environment?, What properties do cells need in order to integrate into the existing circuits? These and other questions have been repeatedly asked in this area of research. In summary, nowadays there are few possibilities to restore nigrostriatal innervation, but novel cell grafts may make it possible. Many cells such as pluripotent stem cells (PSCs), multipotent stem cells (MSCs), olfactory bulb (OB) cells, NTCells are still being studied, but even if we designed the perfect neuron to restore a neural circuit, there still would be a great need to deeply study proliferation and differentiation in order to be able to maintain and control the grafted cells.

Parkinson's Disease

James Parkinson describes *paralysis agitans* in the essay "The shaking palsy" in 1817, and the symptoms were later integrated by Martin Charcot who named it Parkinson's Disease (PD) [14]. PD diagnosis is based on clinical evaluation of motor disabilities such as bradykinesia (slowness of movement), akinesia (poverty spontaneous movements and difficulty in initiating a movement), muscle rigidity, postural instability and resting tremor. These symptoms are results of the subsequent loss of DA neurotransmission and are related to the infiltration of LBs (LBs) and Lewy neurites (LNs) [5, 15]. A clinical consensus has been adopted to report the progress and quantify the symptoms of this illness in 1987, this is the

Unified Parkinson Disease Rating Scale (UPDRS) which still remains the most accepted scale in the world. The UPDRS consist of four parts: The parts I, II and III contain 44 questions measured on a 5-point-scale (0-4). These parts measure behavior and mood, daily life activities and motor skills. The last part of the scale is focused on complying with the requirements for adjunct therapy as well as the complications. According to the infiltration of LBs, Braak has described 6 stages, where stages 1-2 are preclinical and 3-6 correspond to LBs and LNs infiltration into the striatum [4]. The Striatum is a large subcortical structure extensively innervated by DAergic, serotonergic, glutamatergic, and GABAergic inputs (see details in Basal Ganglia section). As a neurodegenerative disorder in PD mainly the nigrostriatal fibers degenerate but the atrophy of nucleus basalis Meynert is also correlated with late Braak stages 5 and 6, and patients with this atrophy also suffer dementia associated with PD [4]. In PD conditions, the indirect pathway is facilitated and the direct pathway seems to be weakened, resulting in hypokinesia [16, 17] Fig. (1).




Fig. (1). Different schematic representation of basal ganglia. **A)** The Classical basal ganglia representation. SNpc; *Substantia Nigra pars compacta*. GPe; *Globus Pallidus externus*. GPi; *Globus Pallidus internus*. SNpc; *Substantia Nigra pars compacta*. **B)** The Oscillatory model which correlate the tremor with an oscillation of 3-10 Hz. In the Parkinsonian state beta oscillations (11-30 Hz) are elevated. The pro-kinetic oscillation is increased in dyskinesia 60–80Hz.

Parkinson's Disease Treatment

When PD is clinically detected, L-DOPA is administered as treatment. L-DOPA is still the gold standard of treatment and is combined with aromatic amino acid decarboxylase inhibitors to avoid the peripheral metabolism of L-DOPA [18]. There is a large sum of evidence showing that with long term exposure to L-DOPA there is a loss of effectiveness during the first 2-5 years and within the following few years increases in dosage are necessary reaching at times 1 gram a day although the maximal recommended dose is 400mg/day [18, 19]. The

SUBJECT INDEX

A

A β deposits clearance 192
 Activated leukocyte cell adhesion molecule (ALCAM) 80
 Adherent dental pulp cells 27
 Adipocytes 2, 3, 27, 82, 83, 84
 Adipogenesis 27, 29, 41, 85, 177
 Adipogenic differentiation 29, 76
 Adipose tissue 3, 4, 22, 54, 72, 79, 85
 Adrenal medulla tissue/cells 212
 Allogenic 50, 54
 DPSCs 50
 stem cells bank 54
 Allo-recognition, indirect 85
 ALP activity 30, 42, 44
 Alveolar bone 23, 29
 Alzheimer's disease 188, 189, 190, 192, 193, 194, 196, 197, 206
 Amelioration 115, 142, 213
 Aminopeptidase 76
 Amygdala 191
 Amyotrophic lateral sclerosis 188, 189, 190, 196
 Angiogenesis 6, 36, 51, 53, 79, 88, 89, 94, 110, 113, 145, 149
 Antibodies, monoclonal 76, 77
 Anti-inflammatory effects 8, 53, 87, 89
 Apical papilla 28
 cells 28
 Apoptosis 77, 88, 89, 106, 173
 Articular cartilage 1, 2
 Astrocytes 53, 191, 192, 193, 213
 Atrial natriuretic factor (ANF) 138, 139
 Autoimmune diseases 71, 87
 Autologous 2, 50, 54, 212, 213
 chondrocyte implantation (ACI) 2
 SHEDs 50
 sources 54
 transplants 212, 213

B

Basal ganglia (BG) 206, 208, 209, 210, 211, 213, 228
 Bilateral Putamen 216, 226
 Body, embryoid 167, 168, 169, 171
 Bone 24, 43, 45, 48, 49
 differentiation 24
 formation 43, 45, 48, 49
 Bone marrow 83, 192, 217, 219
 cells 83
 hematopoietic stem-cells 192
 stem cells (BMSCs) 217, 219
 Bone morphogenetic proteins (BMPs) 39, 40, 131, 133, 136, 138, 149
 Bone tissue 37, 43, 44, 45, 47
 regeneration 43, 45
 Brain derived neurotrophic factor (BDNF) 192, 223

C

Ca²⁺ 171, 172, 173, 174, 175, 176, 177, 178, 179, 180
 cytoplasmic 174, 178
 buffering proteins 178, 179
 channels 172, 173, 177
 exchanger 167, 173, 174, 177
 induced Ca²⁺ release (CICR) 174
 influx 174, 175, 180
 intracellular 175, 178
 release 172, 173, 175, 180
 sparks 175, 176
 transients 171, 175, 176, 177, 178
 Calcineurin 172, 173
 Capacity 7, 24, 30, 31, 50, 72, 79, 85, 168, 178, 212, 217
 vivo self-differentiation 30
 Cardiac cells 172, 174, 176
 differentiated 174

- mature 172
- Cardiac development 128, 130, 137, 138, 149, 179
- Cardiac function 51, 141, 142, 143, 144, 146, 147, 149
 - improvement in 51, 141, 142, 144, 146
 - regional 147, 149
- Cardiac myocytes 138, 141
- Cardiac progenitors 130, 133
- Cardiac stem cells 129, 142, 144, 145, 146, 147, 148, 149
- Cardiac ventricular myocytes 176
- Cardioblasts 130, 131
 - pairs of 131
- Cardiogenic mesoderm 139
- Cardiomyocyte differentiation 134, 136, 168, 169, 170, 171, 173, 174, 175, 176, 177, 178, 179, 180
 - early 173
 - early stages of 174, 175
 - inducing 171
 - signalling antagonizes 173, 176
- Cardiomyocyte differentiation of ESCs 173, 177, 179, 180
- Cardiomyocytes 139, 140, 142, 147, 148, 149, 168, 169, 170, 171, 172, 173, 174, 176, 178, 180
 - adult 174, 176, 178, 180
 - beating 170, 171
 - derived 173, 174
 - differentiation state of 169
 - differentiation to 142, 147, 148
 - functional 139, 180
 - functional specifically-differentiated 168
 - generating 169, 172
 - generation of 140, 149, 172
 - iPSC-derived 180
 - mature 139, 148, 169
- Cardiomyogenesis 136, 139, 148, 149
- Cardiomyogenic differentiation 143, 149
- Cartilage 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 71, 91, 94, 95
 - defects 4, 95
 - diseases 71, 91, 94, 95
 - lesions 1, 3
 - repair 2, 3, 4, 5, 8, 9, 10, 11
- Cartilage injuries 1, 2, 5, 6, 7, 9
 - articular 1, 2, 5
 - treatment of 2
- Cartilaginous tissues 5, 6
- Caudate nucleus 210, 212, 213, 214, 215, 216
- Cavity, pericardial 137
- Cell 4, 5, 6, 9, 10, 11, 22, 23, 28, 31, 32, 40, 42, 44, 45, 46, 72, 76, 87, 93, 118, 119, 141, 142, 192
 - adhesion 42, 44, 45, 46, 76, 118, 119
 - differentiation 5, 192
 - free strategies 9, 11
 - growth 23, 118, 119
 - isolation 22, 93
 - morphology 31, 32
 - populations, adult stem 72
 - proliferation 5, 6, 28, 40, 46, 87
 - purification/Enrichment 141, 142
 - recruitment 4, 5, 9, 10, 11
- Cell replacement 168, 195, 196, 206, 209, 214, 220, 222, 224, 228
 - therapy 195, 196, 214
- Cell-based 3, 4, 21, 35, 37, 53, 93, 116, 117, 180, 188, 197
 - strategies 3, 4
 - therapies 3, 21, 35, 37, 53, 93, 116, 117, 180, 188, 197
- Cells 2, 3, 4, 5, 6, 7, 8, 10, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 51, 53, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 105, 106, 107, 108, 111, 115, 116, 117, 118, 119, 129, 130, 131, 133, 134, 135, 137, 138, 140, 143, 144, 145, 147, 149, 167, 168, 169, 170, 171, 172, 173, 175, 176, 178, 179, 180, 190, 191, 192, 194, 195, 196, 198, 207, 212, 213, 214, 216, 217, 218, 221, 222, 223, 224, 225, 226, 227, 228
 - accessory 3
 - adherent 34
 - apoptotic 89
 - astrocytic 194, 196
 - bioengineered 74
 - cancer 92
 - chondroprogenitor 7
 - damaged 216
 - daughter 26
 - dental 22, 25, 26

- donor 35, 85, 91, 190, 191, 192
 - encapsulated 192
 - endocardial 133
 - endogenous 145
 - engrafted 117, 143
 - epithelial 78, 80, 106, 108
 - expressing 131
 - fetal 225
 - follicle 217
 - grafted 207, 222, 223
 - hematopoietic 26, 32, 82, 143, 149
 - hepatoblastoma 118
 - immune 5, 6, 108
 - implanted 48, 144
 - inflammatory 129
 - infused 73
 - isolated 27, 34, 35, 92
 - malignant 218
 - marrow-derived 83, 143
 - melanoma 80
 - mesenchymal 6, 10, 77, 115, 137, 214, 226
 - mesothelial 137
 - nonparenchymal 105, 107
 - nucleated 91
 - pericardial 130
 - perivascular 26
 - pluripotent 217
 - serotonergic 222, 226
 - synovium-derived 85
 - totipotent 217
 - transfected 39
 - transplantable 119
 - transplanted 168, 226
 - tumor 92
 - vascular 76
 - ventricular-like 169
 - Cell surface 24, 26, 27, 71, 78, 81
 - glycoprotein 78
 - marker 26, 27, 81
 - markers 24, 26, 71
 - Cell survival 5, 6, 89, 94, 212
 - Cell therapy 71, 73, 90, 95, 168, 220, 221
 - Cell transplantation 9, 71, 116, 118, 197, 198, 207, 211, 225
 - Central nervous system 198, 209, 221, 222, 223
 - Ceramic biomaterials 22
 - Chemokines 4, 5, 6, 8, 9, 11, 112, 114, 115
 - Cholangiocytes 106, 107, 118
 - Chondrocytes 2, 3, 4, 5, 6, 7, 82, 84
 - Chondrogenesis 7, 10, 11, 29, 85
 - Chondrogenic differentiation markers 28
 - Chromaffin cells 212
 - stimulated 212
 - Chromaffins 206
 - Chromosomal abnormality 90, 91
 - Collagen type 38, 46, 51, 117
 - Colony forming units (CFU) 3, 24, 72
 - fibroblast (CFUF) 3, 72
 - Cortical neural cells secreting GABA 191
 - Cryopreservation 32, 37, 53
 - Culture 35, 74, 167, 168, 169, 170, 171
 - adherent 171
 - dependent 167, 169, 171
 - microcarrier-based stirred 35
 - monolayer 167, 168, 169, 170
 - suspension 74, 169, 171
 - Cyclic adenosine diphosphate ribose 167, 173, 175
 - Cytokine(s) 4, 5, 8, 9, 11, 52, 53, 79, 80, 87, 88, 89, 106, 111, 112, 113, 114, 115, 223
 - and chemokines 4, 5, 8, 9, 11
 - immunomodulatory 52, 53
 - Cytoplasm 179
- ## D
- DAergic cells 213, 218
 - DAergic neurons 206, 218, 221, 222
 - Deciduous teeth 22, 28, 38, 39
 - exfoliated 39
 - Degenerative diseases 71, 91, 217
 - Dental follicle cells 40
 - Dental pulp 21, 22, 35, 36, 37, 49, 50, 51
 - Regeneration 50
 - stem cells 21, 22, 35, 51
 - tissue 35, 49
 - Dental regeneration 22
 - Dental tissue 38, 39, 43, 49, 50, 53
 - regeneration 39, 49, 50
 - Depression 193, 225, 226
 - Deproteinized bovine bone mineral (DBBM) 45
 - Detection, vivo MSC 79
 - Dexamethasone 40, 42, 46

medium 46
Diastolic depolarization 177
Differentiated cardiomyocytes 135, 142, 170, 173, 180
Differentiation 28, 40, 42, 43, 45, 46, 52, 171, 223, 225
 culture-based 171
 graft 223, 225
 neuronal 28, 52
 osteogenic 40, 42, 43, 45, 46
Differentiation process 175, 178
 cardiomyocyte 178
Differentiation protocols 34, 169, 179
 cardiomyocyte 169
Digestion, enzymatic 32, 33
Dimethyl Sulfoxide (DMSO) 37
DNase 33
Dopaminergic neurons, cells-isolated 196
DPSCs 37, 42, 46, 48, 50
 application, regarding 48, 50
 differentiation of 42, 46
Dyskinesias 209, 210, 211, 221

E

EB-dependent differentiation 169, 171, 172
 and 2D-monolayer culture methods 172
ECM 4, 6, 7, 43, 45, 106, 108, 111, 113, 114, 115, 116, 117M 118, 119, 144
 molecules 4, 6, 7
 proteins 113, 114, 116, 117
 remodeling 113, 114
Effects 51, 89
 antiapoptotic 51
 anti-apoptotic 89
Embryoid body (EB) 167, 168, 169, 171, 176
Embryology 149
Embryonic 27, 227
 dopamine cells 227
 stem cell markers 27
Embryos 135, 136, 138
 chick 135, 136
 murine 138
Endoderm 2, 133, 134, 136, 139, 167, 168, 217
 anterior 136

Endothelial cell(s) 26, 36, 77, 78, 79, 81, 106, 108, 109, 115, 116, 117, 134, 140, 141, 142, 145, 148
 functions, additional 116
 human 79
 lining 106
 proliferation 36
 vascular 79
Endothelial progenitor cells (EPCs) 51, 108, 110, 128, 142, 143
Engrafting host tissues 36
Epicardium derived cells 142
Epidermal growth factor (EGF) 34, 94, 109, 110
ESC-derived cardiomyocytes 170, 171, 173, 174, 175, 176, 177, 178
 human 176, 178
Excitation-contraction (EC) 81, 169, 174, 191, 192
Expressed stem cell markers 31
Extracellular vesicles 1, 8
Extracorporeal systems 105, 118

F

Factors 7, 94, 172, 173, 193, 223
 immunomodulatory 7, 94
 neurotrophic 193, 223
 nuclear 172, 173
Fetal bovine serum (FBS) 33, 34, 40, 41
Fibroblast growth factor (FGFs) 6, 92, 113, 115, 131, 134, 138, 149, 173, 176
Fibronectin 76, 77, 114
Freeze-dried bone allograft (FDBA) 45

G

GABAergic interneurons 211
Gastrulation 135, 136, 137
Genes 26, 41, 42, 51, 131, 133, 136, 139, 173, 179
 bone-related 41
 differentiation marker 26
Genetic studies 196
Germ cells 81, 217
 human embryonic 81
Germ stem cells (GSCs) 219

- Glial derived neurotrophic factor (GDNF) 223
Globus Pallida externa (GPe) 208, 210, 214
Good manufacturing practice (GMP) 93
Graft induced dyskinesias (GIDs) 216, 220, 221, 222
Grafts 47, 142, 195, 206, 207, 211, 212, 213, 214, 215, 217, 218, 220, 221, 222, 223, 224, 225, 226, 227
 responsiveness of 225, 226
Granular deproteinized bovine bone 38
Granulocyte-colony 39, 51, 52
Growth factors 3, 4, 6, 8, 9, 10, 11, 21, 22, 26, 35, 52, 54, 82, 88, 89, 94, 106, 111, 113, 114, 115, 116, 139, 144, 170, 171, 172, 212, 225
- H**
- Heart 132, 134, 135, 138, 148
 3-chambered 132, 134
 tubular 135, 138, 148
Heart cell identities 131
Heart development 130, 133, 139, 140, 148, 179, 180
 embryonic 139
 human 139, 140
Heart diseases 128, 129, 146, 147, 167, 168, 170, 180
 ischemic 128, 129, 146, 147
Heart progenitors 130, 131
Hematopoietic 27, 72, 76, 81, 82, 83, 106, 107, 108, 109, 110, 112, 113, 114, 115, 116, 117, 118, 128, 141, 143, 149, 216, 217, 218
 BM cells 81
 stem and progenitor cells 141, 143
 stem cell (HSCs) 27, 72, 76, 82, 83, 106, 107, 108, 109, 110, 112, 113, 114, 115, 116, 117, 118, 128, 143, 149, 216, 217, 218
Hepatic 105, 106, 107
 sinusoids 106, 107
 stem cells 105
Hepatocytes 6, 7, 27, 87, 88, 89, 105, 106, 107, 108, 109, 110, 113, 114, 115, 116, 117, 118, 119
 damaged 110
 functions of 118, 119
 growth factor (HGF) 6, 7, 87, 88, 89, 106, 109, 110, 113, 114, 115
 mature 106, 117, 119
 primary 116, 117
 proliferation of 108, 115
Heterogeneity, dependent 76
HGF, expressing 110
Hippocampus 191, 192, 193, 194, 222
Host myocardium 144
HSCs activation 112, 113
Human derived mesenchymal stem cells
 populations 32
Human EC cells 82
Human embryonic stem cells 81, 117, 139, 142, 148, 190, 192, 194, 195
Human leukocyte antigen (HLAs) 3, 85, 87
Huntington's disease 50, 52, 188, 189, 190, 196
Hyaluronic acid 48
Hypoplastic Left Heart Syndrome (HLHS) 146
- I**
- IL-1 β -induced expression 7
Immunoglobulin superfamily 78, 80
Immunomodulatory properties 35, 87, 88
Inflammatory responses 7, 94, 107
Inner cell mass (ICM) 2, 168, 217, 219
Insulin growth factor (IGF) 6
International society for cellular therapy (ISCT) 3, 75, 76, 78, 79
Ischemic 128, 129, 146, 147
 cardiomyopathy 146, 147
 heart disease (IHD) 128, 129, 146, 147
- K**
- Keratinocyte growth factor (KGF) 94
Kupffer cells (KCs) 105, 106, 107, 108, 110, 111, 112, 113, 116, 117, 118
- L**
- Left ventricular (LV) 51, 132, 140, 141, 143, 146

- dysfunction 146
 - end diastolic pressure (LVEDP) 141
 - Levodopa Induced dyskinesias (LIDs) 222
 - Lewy neurites (LNs) 207
 - Limbal stem cell deficiency (LSCD) 51
 - Liver fibrosis 108, 114
 - Liver injury 106, 107, 108, 110, 111, 113, 114, 115, 118
 - chronic 107, 108, 110, 118
 - models of 111, 113
 - Liver progenitor cells (LPCs) 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 119
 - Liver sinusoidal endothelial cells (LSECs) 105, 106, 107, 108, 109, 110, 113, 115, 116, 117
 - Liver stem cell response 113
 - Liver tissue 105, 115, 117, 119
 - functional 117
 - LPC(s) 105, 108, 110, 111, 112, 113, 114, 115, 117, 118
 - and parenchymal cells 105
 - derived lymphotoxin beta (LTb) 113, 114
 - differentiation of 112, 113, 115, 117
 - expansion of 108, 110, 111, 113, 115
 - proliferation 108, 110, 112
 - response 111, 113, 118
 - LSECs activation 108, 109, 110
 - L-type Ca²⁺ channels (LTCCs) 167, 168, 173, 174, 175, 177, 180
 - LV remodeling 142, 144
 - Lymphocytes 6, 78, 79, 87, 106, 107
- M**
- Macrophage 5, 8, 10
 - inflammatory protein (MIP) 5
 - polarization 8, 10
 - Magnetic fields 78
 - Mandibular defects 45
 - Marrow cells, human bone 76
 - Matrix extracellular phosphoglycoprotein (MEPE) 42
 - Medial migratory stream (MMS) 223
 - Melanoma cell adhesion molecule (MCAM) 79
 - Membrane, synovial 4, 80, 81
 - Mesenchymal 2, 3, 24, 27, 83, 141
 - precursor cells (MPCs) 141
 - stem cell antigen-1 83
 - stem cell-based therapies 3
 - stem cell features 27
 - stem cell markers 24, 27
 - stromal/stem cells 2, 3
 - Mesoderm 2, 128, 130, 131, 134, 137, 138, 143, 167, 168, 217
 - dorsal 131
 - splanchnic 134, 138
 - Mesodermal cells 133, 135, 136, 137, 138, 139
 - cells proliferate 137
 - ventral 135
 - Mesoderm induction 139
 - Metabolites, biocompatible 43
 - MicroRNAs 8, 9
 - Mineralized tissues 27, 38, 39, 41, 42, 44, 45, 46, 48
 - formation 38, 48
 - regeneration applications 38
 - formation 27, 41
 - Minimal stem cells characteristics, displayed 26
 - Mixed cells dopaminergic and serotonergic neurons 220
 - Molars hyaluronic acid 38
 - Monocyte-derived dendritic cells 87
 - Monolayer 170
 - based cardiomyocyte differentiation methods 170
 - cardiomyocyte differentiation method 170
 - Mononuclear cells 3, 82, 143, 146, 147, 192
 - isolated 3
 - Motor improvement 215, 216, 220
 - MSCs 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 36, 38, 76, 77, 78, 81, 88, 90, 92, 93, 94
 - adipose tissue-derived 6, 76
 - endogenous 5, 10
 - in tissue repair 3, 93
 - marker for 77, 78, 81, 82
 - parietalis-derived 81
 - placenta-derived 80, 81, 88
 - populations, derived 36, 38
 - secretome 1, 2, 3, 4, 8, 9, 11
 - transplantation 90, 92, 94
 - Multilineage 3, 72, 84

-differentiating stress enduring 72, 84
adult progenitor cells (MAPCs) 72
adult stem cells (MASCs) 3, 72
Multipotent cells 2, 141
 expanded BM 141
 undifferentiated 2
Murine muscle cells 51
Myocardial infarction (MI) 51, 89, 128, 129,
 144, 145, 146, 148
Myocardial tissue 129, 134, 149
 damaged 129, 149
Myocardial viability 146
Myocardin 135, 179
Myocardium 129, 136, 141, 144
Myocyte enhancer factor 131

N

Nerve regeneration 22, 39, 52, 53, 54
 peripheral 52, 54
Neural cells 190, 195, 196, 218, 220
 cell-derived 190
Neural stem cells (NSCs) 188, 190, 191, 192,
 193, 194, 218, 220, 225
Neural stem/precursor cells (NSPCs) 192, 193,
 199
Neuroblastoma cells 192
Neurodegenerative 53, 188, 190, 192, 193,
 196, 199, 206, 207, 208, 224, 226
 diseases 53, 188, 190, 192, 196, 199, 206,
 207, 224, 226
 disorders 188, 190, 193, 196, 199, 208
Neurogenesis 212, 222, 223, 224
Neurogenic niches 222, 223
Neuronal cells 193, 195, 196
 born 193
Neuronal-like cells 53
Nicotinamide adenine dinucleotide (NAD) 175
Nicotinic acid adenine dinucleotide phosphate
 (NAADP) 175
NK cells, activated 86
Nonhealing wounds 93, 94
Notch receptors 42
Nuclear transfer 217, 219
Nucleated BM cells 84
Nuclei, subthalamic 209, 210
Nucleic acids 8, 9

O

OA chondrocytes 7, 8
Orai1-mediated SOCE 176, 177
Oro-maxillo-facial (OMF) 47
Osteoarthritis 1, 2, 9
Osteoblasts 2, 3, 42, 48, 50, 82, 84, 95
Osteocytes 48
Osteo-differentiation 22, 43
Osteogenic regeneration 38, 45

P

Parenchymal cells 105, 106, 108, 109
Partial hepatectomy (PH) 105, 109, 112, 113,
 119
Periodontal Ligament (PDLSCs) 29, 31, 33,
 34, 40, 50, 80, 82
Perivascular niche 24, 25
Phenotypical characteristics 73, 74, 84
Phospholamban 143, 173, 177, 178
Phosphorylation 173, 176, 177, 179
Pilocarpine 191
Plasma membrane 173, 174, 177, 178
Platelet rich plasma (PRP) 34, 35, 49
PLGA membranes 43, 44
Pluripotency 2, 27, 167, 168
Pluripotent 2, 128, 190, 196, 207, 217, 219,
 223, 225
 stem cells (PSCs) 2, 128, 190, 196, 207,
 217, 219, 223, 225
 stem cells technology, induced 196
Population 26, 34, 35
 dental cells 35
 doublings 26, 34
Porcine dental stem cells 31
Precursor cells 81, 130, 141, 194, 226
 cardiac 130
 mesenchymal 141
 neuronal 226
 primitive 81
Progenitor cells 2, 6, 24, 29, 51, 72, 73, 74, 77,
 106, 108, 109, 110, 138, 139, 141, 142,
 143, 145, 144, 146, 147, 148, 172, 188,
 195, 196
 accounts 110
 bipotential 106

cardiac 145, 172
 dental follicle 29
 derived 147
 early heart 138
 endogenous cardiac 142
 endothelial 51, 108, 110, 142, 143
 hepatic sinusoidal 110
 induced neural 188, 195, 196
 marrow-derived sinusoidal 110
 multilineage 72
 neural 6
 Progenitors, hematopoietic 77, 78
 Projection neurons 209, 211
 Properties 79, 169, 170, 176, 179, 210
 electrophysiological 169, 170, 176, 210
 maintaining stem cell 79
 Prostaglandin E2 7, 86, 87
 Proteins, amyloidogenic 189
 Pulp tissues 25, 28, 35, 37
 Putamen nucleus 212, 216, 220, 221

R

Receptors 43, 78, 80, 83, 109, 110, 113, 115,
 167, 172, 173, 174, 197, 210, 212
 inositol 1,4,5-trisphosphate 167, 172
 motif 109
 nuclear 43
 ryanodine 167, 173, 174
 transferrin 78
 Regeneration 1, 3, 4, 5, 9, 10, 11, 22, 23, 24,
 31, 38, 39, 49, 53, 72, 73, 89, 95, 108,
 128, 144, 145, 147, 150, 197, 222
 cardiomyocyte 145, 147
 factors 22, 23, 38, 39
 sinusoidal 108
 Regenerative 73, 74, 143, 188, 206
 medicine, perspective of MSCs in 73, 74
 therapy 143, 188, 206
 Regulating cardiomyocyte differentiation 167,
 172
 Resident perisinusoidal cells 107
 Retinal ganglion cells 53
 Retinoic Acid (RA) 40, 132, 140
 Retrieved memory 191, 192
 Rostral migratory stream (RMS) 222, 223

S

Sarcomeric structures 171, 172
 Sarcoplasmic reticulum (SR) 150, 167, 173,
 174, 175, 177, 178
 Sclerosis, lateral 188, 189, 190, 196
 Secretome factors 4, 7, 11
 Semi-direct allo-recognition 85, 86
 Sendai virus 218, 219
 Serum response factor (SRF) 135
 Sinusoidal progenitor cells (SPCs) 110
 Skeletal 72, 142, 144
 muscle satellite cells 144
 myoblasts 142, 144
 stem cells (SSCs) 72
 Somatic cells 2, 195, 217, 218, 219
 Spinal muscular atrophy 188, 190, 196
 SR via the sarco/endoplasmic reticulum Ca²⁺-
 ATPase (SERCA) 167, 168, 173, 174,
 177, 178, 180
 SSEA-4-expressing cells 82
 Static magnetic field (SMF) 42
 Stellate cells 105, 106, 107, 113, 114, 118
 hepatic 105, 106, 107, 113
 Stem cells 2, 22, 23, 24, 25, 27, 28, 29, 31, 32,
 39, 40, 41, 43, 48, 50, 51, 52, 53, 54, 55,
 71, 72, 73, 76, 79, 81, 82, 83, 88, 91, 92,
 96, 109, 117, 119, 128, 130, 139, 140,
 141, 143, 144, 145, 146, 148, 149, 188,
 190, 192, 193, 194, 195, 198, 199, 206,
 216, 217, 218, 223, 226
 activities 24
 adipose derived 146, 192
 adipose-derived 53
 adipose tissue-derived 41
 advantages 73
 adult neural 193
 allogenic 54
 antigen-1 82
 apical papilla 29
 blood-derived mesenchymal 192
 cancer 79
 deciduous teeth 28
 dental 22, 23
 derived 32, 50, 146, 226
 derived mesenchymal 144, 146, 148
 differentiation 139, 194

expanded BM multipotent 141
factor (SCF) 141
hematopoietic 27, 72, 82, 109, 143, 217, 218
human dental pulp 50
human induced pluripotent 195
human neural 76
human pluripotent 117
human pluripotent liver19
human teratocarcinoma 81
isolating human 199
lines 195
marrow-derived mesenchymal 53, 192
maximized 96
mobilized dental pulp 39, 51, 52
multipotent 207
multipotent Germ 217
neural derived 192
neuronal 193
personalized pluripotent 2
post-injury grafting of neural 193, 194
primary human mesenchymal 83
primitive pluripotent 27
secretome 145
skeletal 72
therapies 54, 91, 128, 188, 190, 198, 199
tissue-intrinsic 88
transplantation 52
transplants 198, 206
treatments, effective 128
Stem/progenitor cells 25, 144, 146
Store-operated Ca^{2+} entry (SOCE) 167, 168, 173, 176
Stromal cells 26, 72, 190
 mesenchymal 72, 190
Stromal derived factor (SDF) 109
Substantia nigra (SN) 206, 208, 212, 214, 222, 226
Subthalamic nucleus (STN) 208, 209, 210, 211, 214
Surface markers expression 28, 29
Swine 31, 38, 39
 cells 31
 deciduous 38, 39
Sympathetic ganglion cells 221

T

Target neighboring cells 114
T-cells, activated 94, 172, 173
Temporal lobe epilepsy 53, 192, 193
Tetraspanins 8
Therapeutic outcome 190, 191, 192
Therapies 4, 9, 11, 21, 22, 52, 54, 86, 87, 119, 169, 190, 193, 197, 198, 199, 209
 auto-MSC 86, 87
 based 22, 52, 54, 190
 cell-based MSC 9, 11
 cell-free 4, 9
 neural stem cell transplantation 198
 stem cell neuroreplacement 199
Tinman expression 131
Tissues 1, 2, 3, 4, 5, 6, 11, 21, 22, 23, 24, 27, 29, 30, 32, 37, 40, 41, 43, 44, 46, 48, 49, 51, 52, 54, 55, 71, 72, 73, 76, 80, 82, 83, 84, 91, 93, 94, 95, 105, 109, 112, 115, 119, 134, 135, 145, 146, 148, 150, 170, 177, 195, 212, 213, 214, 215, 216, 218, 220, 221, 224, 225, 226, 227
 atrial 134, 135
 cardiac 145, 148
 culture 145, 170
 engineering 1, 11, 21, 22, 23, 37, 43, 44, 48, 49, 51, 52, 55, 71, 73, 91, 94, 105, 115, 119
 formation 6, 40, 41
 function 22
 grafts 215, 221, 225
 homeostasis 6, 24
 injuries 2, 6, 109
 repair 1, 2, 3, 4, 5, 71, 91, 93, 94, 95, 150
Tissue regeneration 1, 22, 23, 37, 43, 51, 39
 applications 37, 51
 mineralized 37, 43
Transcriptional regulators 138
Transcription factors 29, 51, 131, 138, 139, 149, 168, 218
Transforming growth factor (TGF) 6, 39, 87, 106
Transient receptor potential (TRP) 167, 173, 177

Transplantation 3, 22, 51, 73, 74, 83, 87, 90,
91, 93, 95, 105, 119, 168, 188, 198, 224
systemic 91, 93, 95
Transplanted allogeneic cells 85
Trophic 1, 3, 4, 192, 193
factors 1, 3, 4
support 192, 193
Tumorigenesis 198, 218, 224, 225
Tumor necrosis factor (TNF) 5, 87, 113, 223
Tunel-positive cells 89

U

Umbilical cord (UC) 27, 34, 35, 79, 81, 88,
141, 146, 147, 148, 192
blood (UCB) 34, 35, 81
Undifferentiated cells 22, 26, 28, 218
grafts 218
implanted 26
responsive 22

Unified Parkinson disease rating scale
(UPDRS) 208, 213, 216, 218, 220, 221
Unrestricted somatic stem cells (USSC) 72

V

Vascular endothelial growth factor (VEGF)
36, 42, 44, 46, 53, 88, 92, 94, 108, 109,
110, 113, 115, 139, 170
Ventral mesencephalon 213, 214, 215, 216,
220, 225, 226
human 214
Ventricular remodeling 141, 143, 146
Very small embryonic-like (VSELs) 72, 79
Viral system 219

W

Wnt signaling 136
Wound repair 94



ATTA-UR-RAHMAN, FRS

Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1080 international publications in several fields of organic chemistry including 751 research publications, 37 international patents, 69 chapters in books and 221 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world's leading encyclopedic series of volumes on natural products "Studies in Natural Product Chemistry" 54 volumes of which have been published under his Editorship by Elsevier during the last two decades.

Prof. Rahman won the UNESCO Science Prize (1999) and was elected as Fellow of the prestigious Royal Society (London) in July 2006. He has been conferred honorary doctorate degrees by many universities including (Sc.D.) by the Cambridge University (UK) (1987). He was elected Honorary Life Fellow of Kings College, Cambridge University, UK, conferred the TWAS (Italy) Prize and the Austrian government has honoured him with its high civil award ("Grosse Goldene Ehrenzeischen am Bande") (2007). He is Foreign Fellow of Chinese and Korean Academy of Sciences, Foreign Fellow of the Chinese Chemical Society and former President of Pakistan Academy of Sciences.



SHAZIA ANJUM

Dr. Shazia Anjum is the Professor of the Chemistry Department and the Director of Cholistan Institute of Desert Studies, at the Islamia University of Bahawalpur, Pakistan. She is an experienced medicinal and natural product chemist. She has authored and co-authored more than 108 research papers, a US patent, has edited 05 books and has published 03 chapters in international books. She has accomplished the synthesis of several naturally occurring aminoglycosides- that can be used as antibiotics. A dozen of students have completed their MS degrees under her supervision and couple of others are pursuing their MS/PhD degrees.

As recognition of her contributions to science, she has been awarded with 03 International awards like Fellowship from the *Islamic World Academy of Sciences*, Postdoctoral fellowship from the *Ministry of Culture and Education, Spain* and a Young Chemist Award from the *Third World Academy of Sciences, Italy*. She also has several national awards to her credit.